Literature DB >> 22706563

[Bevacizumab in therapy-refractory epistaxis: case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia].

C Rohrmeier1, T S Kühnel.   

Abstract

We report on the submucosal injection of bevacizumab (Avastin) at a dose of 0.3 to 3.75 mg per side in a patient with hereditary hemorrhagic telangiectasia. Application of such low doses has not been described in the literature yet. Our case report shows the positive effect of low-dose bevacizumab on therapy-refractory epistaxis. No complications were caused by the bevacizumab treatment.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22706563     DOI： 10.1007/s00106-011-2458-x

Source DB:  PubMed          Journal:  HNO        ISSN： 0017-6192            Impact factor:   1.284


  9 in total

1.  Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab.

Authors:  Dimitri Flieger; Sabine Hainke; Wolfgang Fischbach
Journal:  Ann Hematol       Date:  2006-06-29       Impact factor: 3.673

2.  Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.

Authors:  Tom T Karnezis; Terence M Davidson
Journal:  Laryngoscope       Date:  2010-12-16       Impact factor: 3.325

3.  Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.

Authors:  Sonia Chen; Tom Karnezis; Terence M Davidson
Journal:  Laryngoscope       Date:  2010-11-11       Impact factor: 3.325

4.  Clinical strategy in hereditary hemorrhagic telangiectasia.

Authors:  Thomas S Kühnel; Birgit H Wagner; Christian P Schurr; Jürgen Strutz
Journal:  Am J Rhinol       Date:  2005 Sep-Oct

5.  Morphology and distribution of nasal telangiectasia in HHT-patients with epistaxis.

Authors:  Benedikt J Folz; Ana Cerra Wollstein; Burkard M Lippert; Jochen A Werner
Journal:  Am J Rhinol       Date:  2005 Jan-Feb

Review 6.  Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred.

Authors:  J E McDonald; F J Miller; S E Hallam; L Nelson; D A Marchuk; K J Ward
Journal:  Am J Med Genet       Date:  2000-08-14

7.  Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia.

Authors:  Anna Cirulli; Arcangelo Liso; Francesco D'Ovidio; Anna Mestice; Giovanna Pasculli; Mauro Gallitelli; Rita Rizzi; Giorgina Specchia; Carlo Sabbà
Journal:  Acta Haematol       Date:  2003       Impact factor: 2.195

Review 8.  [Hereditary hemorrhagic telangiectasia (Osler's disease). An interdisciplinary challenge].

Authors:  U W Geisthoff; G Schneider; J Fischinger; P K Plinkert
Journal:  HNO       Date:  2002-02       Impact factor: 1.284

Review 9.  [Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series].

Authors:  C H Meyer; H-M Helb; N Eter
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059
  9 in total
  2 in total

1.  Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab.

Authors:  Jee Wan Wee; Young Woo Jeon; Jun Young Eun; Han Jo Kim; Sang Byung Bae; Kyu Taek Lee
Journal:  Blood Res       Date:  2014-09-25

2.  Syndrome in question.

Authors:  Sheila Itamara Ferreira do Couto Meireles; Sônia Maria Fonseca de Andrade; Maria Fernanda Gomes; Fernanda Aalmeida Nunes Castro; Antonio José Tebcherani
Journal:  An Bras Dermatol       Date:  2014 Jul-Aug       Impact factor: 1.896
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.